Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oblimersen and Docetaxel in Advanced Solid Tumors and Prostate Cancer
NCT00003103Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 1997
- Primary completion
- Aug 2002
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of oblimersen in prostate cancer (PCa), solid tumor, sponsored by Memorial Sloan Kettering Cancer Center. Started Aug 1997; status: completed.
02
Drugs
oblimersen
03
Conditions
prostate cancer (PCa)solid tumor
Beyond the preview
Go deeper on NCT00003103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003103.